New Delhi, April 2 Emcure Pharmaceuticals announced on Thursday a reduction in the price of its weight management drug, Poviztra, a semaglutide injection, by up to 55 per cent to improve patient access.
The starting dose of Poviztra (0.25 mg) will now be available for Rs 3,999 per month (inclusive of taxes), a reduction of 55 per cent from the previous price of Rs 8,790, with the price reduction taking effect from April 3, 2026.
Across all doses, the price of Poviztra has been reduced by an average of 47 per cent. The drug is available in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg.
Poviztra is the second brand of Novo Nordisk's semaglutide injection for obesity, and will be exclusively distributed and commercialized by Emcure Pharma in India.
Novo Nordisk India announced price reductions for Ozempic and Wegovy in India on Tuesday, days after the launch of generic versions of semaglutide injections for patients living with type 2 diabetes and obesity.
Indian pharmaceutical companies recently announced the launch of their generic versions following the availability of the molecule behind products like Ozempic and Wegovy, which went off-patent in India.
"As the first Indian company to exclusively distribute and commercialize Poviztra, a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price," Emcure Pharmaceuticals said in a statement.
Satish Mehta, CEO and Managing Director of Emcure Pharma, emphasized that this price revision is a vital step towards addressing the obesity epidemic in India, with nearly 254 million people living with generalized obesity.
"The reduced pricing will support Emcure’s ongoing commitment to improving health outcomes and increasing access to scientifically validated weight-management therapies," he added.